Torrent Pharmaceuticals Limited on Monday announced its financial results for the first quarter of FY26. The net profit has grown 20 per cent, driven by robust sales growth across key territories.
According to an official release, the revenue at Rs 3,178 crore, grew by 11 per cent YoY and the operating EBITDA at Rs 1032 crore is up by 14 per cent YoY.
The release further added that the operating EBITDA margin has been at 32. per cent and the gross margin has been 76 per cent.
The figures include acquisition related one-off expenses of Rs. 15 crores. Operating EBITDA adjusted for these one-offs is Rs. 1,047 crores, with a margin of 32.9 per cent.
The company’s net profit after tax stood at Rs. 548 crores, which is up by 20 per cent YoY.
The company further said that India revenues are at Rs 1,811 crore, up by 11 per cent. It was led by outperformance in focus therapies.
As per AIOCD secondary market data, IPM growth for the quarter was eight per cent.
Torrent’s chronic business grew at 13 per cent vs IPM growth of 9 per cent. The company has 21 brands in the Top 500 brands in IPM, with 14 brands having more than Rs.100 crore sales.
The company said that revenues in Brazil are at Rs 218 crore, up by 11 per cent. Constant currency revenues are at R$ 143 million, up by 16 per cent. As per IQVIA, Torrent grew at 14 per cent vs market growth of 5 per cent.
Growth was aided by the performance of top brands & new launches.
Torrent has 62 products under ANVISA review.
In Germany revenues have been at Rs 308 crore, up by 9 per cent. Constant currency revenues at EUR 32 million, were up by 1 per cent.
Growth was impacted due to supply disruption at third party supplier.
US business revenues are at Rs 308 crore, up by 19 per cent.
Constant currency revenues at $36 million, were up by 16 per cent compared to same period in the previous year. Recent launches have achieved targeted market shares.
Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology.
Also Read: Dubai-Based Man Accused of ₹4 Crore Work Permit Scam Targeting Indian Youth https://www.vibesofindia.com/dubai-based-man-accused-of-%e2%82%b94-crore-work-permit-scam-targeting-indian-youth/
